Boehringer Ingelheim has introduced a new artificial intelligence (AI) and machine learning (ML) facility in London, strengthening its efforts to integrate advanced technologies into pharmaceutical research. The AI R&D centre will focus on applying AI models to support the discovery and development of targeted medicines, particularly for patients with unmet medical needs.
Located in King’s Cross, the Computational Innovation site forms part of a broader £150m ($202.7m) investment programme spread across 10 years. The company expects the initiative to enhance its ability to understand biological processes that influence patient outcomes, while also improving identification of mechanisms with a higher likelihood of success in drug development. The London facility joins similar AI-focused sites already operating in the US, Austria, and Germany, expanding Boehringer’s global research footprint.
The company indicated that the site will help accelerate development timelines and improve decision-making in R&D. Activities at the AI R&D centre will include building foundational AI models to analyse patient journeys, identify disease drivers, and determine root causes, ultimately supporting the development of more precise therapies. The facility, which officially opened on 20 April, is expected to onboard its first 50 AI specialists by the end of 2027.
Paola Casarosa, global head, innovation unit at Boehringer Ingelheim, commented: “Establishing a presence in London allows us to leverage the UK’s rich data resources and infrastructure, while connecting with world-class talent across academia, biotechnology and AI ecosystems to enable innovation for patient benefit.” The move aligns with wider ambitions to strengthen London’s life sciences ecosystem, particularly following the London Cancer Hub’s $1bn expansion announcement in February 2026. UK science minister Lord Patrick Vallance added: “AI is unlocking opportunities to advance discovery in life sciences like never before and Boehringer’s decision to open its new hub in King’s Cross will ensure they can both access and contribute to a flourishing base for innovation in London.”
